Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AngioDesign Tailoring Next-Generation ACE Inhibitors

Executive Summary

Mario Ehlers, chairman of drug discovery group Angio-Design (UK) tells Sten Stovall why the design of specific domain-selective ACE inhibitors is expected to produce next-generation drugs that are safer and more effective - and generate blockbuster returns.